Document is current
Any future updates will be listed below
-
Authors
Garside, Helen
Aslamkhan, Amy
Daniels, Danette L. https://orcid.org/0000-0002-7659-3020
Datta, Kaushik
Egebjerg, Mikael https://orcid.org/0000-0001-5258-2442
Hukkanen, Renee R. https://orcid.org/0000-0002-0348-7585
Jones, Lyn H. https://orcid.org/0000-0002-8388-5865
Ketter, Natalie
Lahoti, Tejas S.
Loberg, Lise I.
Messmer, Davorka
O’Lone, Raegan
Pastoor, Timothy
Pavkovic, Mira
Pereira Mouriès, Lucilia https://orcid.org/0000-0001-5836-6011
Rankovic, Zoran
Rengarajan, Aishwarya
Vargesson, Neil https://orcid.org/0000-0001-8027-114X
Vicart, Axel
Wange, Ronald L. https://orcid.org/0000-0001-9593-3572
Yanochko-Hoffman, Gina
Roberts, Ruth https://orcid.org/0000-0002-7763-7558
Sidaway, James
- License Information
-
More Information
Article History
Accepted: 17 March 2026
First Online: 20 April 2026
Competing interests
: H.G., J.S. and R.R. are employees of ApconiX, an integrated drug safety and research laboratory consultancy. A.A., K.D. and A.R. are employees of Merck & Co, a company involved in developing TPDs. D.L.D. is an employee of Foghorn Therapeutics, a company involved in developing TPDs. M.E. is an employee of Novo Nordisk, a company involved in developing TPDs. R.R.H. is an employee of Amgen, a company involved in developing TPDs. L.H.J. is a is a co-founder of Anvia Therapeutics, an adviser to companies developing TPDs, and holds equity in Hyku Biosciences and Rapafusyn Pharmaceuticals. L.H.J. previously received funding from Deerfield at the Center for Protein Degradation at Dana Farber Cancer Institute. N.V. is an employee of The University of Aberdeen and holds patents on thalidomide analogues. T.S.L. is an employee of Takeda, a company involved in developing TPDs. L.I.L. is an employee of Abbvie, a company involved in developing TPDs. D.M. is an employee of Nurix Therapeutics, a company involved in developing TPDs. L.P.M. and R.O’L. are employees of HESI, an organization that works with scientists from industry (including companies developing TPDs) to solve complex scientific issues. A.V. is an employee of Novartis, a company involved in developing TPDs. G.Y.-H. is an employee of Johnson & Johnson, a company involved in developing TPDs. M.P. is an employee of Bayer AG, a company involved in developing TPDs. Z.R. is director of TPD-focused drug discovery centre at the Institute of Cancer Research and holds patents on cereblon-dependent degraders. N.K. is an employee of Boehringer Ingelheim, a company involved in developing TPDs. R.L.W. is an Employee of Aclairo Pharmaceutical Development Group, a company that provides scientific and regulatory advice to companies developing TPDs. T.P. holds a consulting contract and Incentive Units in Oerth Bio, an LLC that discovers and develops agricultural TPD compounds.
